Mesoblast Ltd - Company Profile
Powered by 
All the sales intelligence you need on Mesoblast Ltd in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Mesoblast Ltd fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Mesoblast Ltd.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Mesoblast Ltd (Mesoblast) is a regenerative medicine company that develops regenerative cell-based products. Its lead candidate, remestemcel-L, is in Phase III clinical trials under the brand name Ryoncil for the treatment of pediatric steroid-refractory acute graft versus host disease (SR-aGVHD). Mesoblast is advancing rexlemestrocel for localized inflammatory diseases, including advanced heart failure, end-stage ischemic heart failure, and MPc-06-ID (rexlemestrocel) for the treatment of chronic low back pain. The company leverages its proprietary technology platform to create treatments for cardiac and hematological diseases, mesenchymal lineage adult stem cells (MLCs), spine and musculoskeletal disorders, and immune-mediated and inflammatory conditions.
Headquarters
Australia
Address
L 38, 55 Collins St, Melbourne, Victoria, 3000
Website
www.mesoblast.com
Telephone
61 3 96396036
No of Employees
81
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
MSB (ASX)
Revenue (2024)
$17.2M
191.4%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
-16.1%
(2024 vs 2023)
Market Cap*
$1.8B
Net Profit Margin (2024)
XYZ
60.2%
(2024 vs 2023)
* As of and is in US$
Mesoblast Ltd premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Pipeline | Revascor |
| Remestemcel-L: | Ryoncil |
| Steroid-Refractory Acute Graft Versus Host Disease (Children) | |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | New Products/Services | In January, the company introduced Ryoncil (remestemcel-L) for steroid-refractory acute graft-versus-host disease in pediatric patients. |
| 2024 | Regulatory Approval | In December, the company received approval from the US FDA for Ryoncil, a mesenchymal stromal cell (MSC) therapy. |
| 2024 | Regulatory Approval | In February, the company received approval from the US Food and Drug Administration for its allogeneic cell therapy Revascor (rexlemestrocel-L) from the randomized controlled trial in children with hypoplastic left heart syndrome. |
Competitor Comparison
| Key Parameters | Mesoblast Ltd | Cynata Therapeutics Ltd | Allogene Therapeutics Inc | Amniotics AB | BioSenic SA |
|---|---|---|---|---|---|
| Headquarters | Australia | Australia | United States of America | Sweden | Belgium |
| City | Melbourne | Cremorne | San Francisco | Lund | Mont-Saint-Guibert |
| State/Province | Victoria | Victoria | California | - | - |
| No. of Employees | 81 | - | 150 | 9 | 7 |
| Entity Type | Public | Public | Public | Private | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Silviu Itescu | Chief Executive Officer; Director; Managing Director | Executive Board | 2011 | - |
| Eric Rose, MD | Chief Medical Officer; Director | Executive Board | 2022 | - |
| James M. O’Brien | Chief Financial Officer | Senior Management | 2025 | - |
| Philip J. Facchina | Chairman | Non Executive Board | 2026 | - |
| Geraldine Storton | Head - Regulatory Affairs and Quality Management | Senior Management | 2015 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer